Clinical Report: Assessing Temporal Changes in Retinal Non-Perfusion Using Ultra-Widefield Fluorescein Angiography After Intravitreal Therapy for Diabetic Retinopathy

Overview

This study investigates the longitudinal changes in retinal non-perfusion and neovascularization in diabetic retinopathy patients following intravitreal therapy, utilizing ultra-widefield fluorescein angiography (UWF FA). The findings suggest that UWF FA can provide valuable insights into disease progression and treatment response over time.

Background

Diabetic retinopathy (DR) is a leading cause of preventable blindness, affecting millions globally. The prevalence of DR is expected to rise significantly, highlighting the need for effective monitoring and treatment strategies. Ultra-widefield fluorescein angiography (UWF FA) offers enhanced visualization of retinal non-perfusion, which is crucial for assessing disease severity and treatment outcomes.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

• Diabetic retinopathy is projected to affect 16 million individuals in the U.S. by 2050.
• UWF FA captures 82% of the retinal surface, significantly more than traditional methods.
• Intravitreal anti-VEGF therapy is first-line treatment for center-involving diabetic macular edema.
• Longitudinal studies using UWF FA have shown non-perfusion may not change significantly despite improvements in DR severity.
• UWF FA can help quantify changes in the foveal avascular zone and neovascularization areas over time.

Clinical Implications

The use of UWF FA in clinical practice can enhance the assessment of diabetic retinopathy and guide treatment decisions. Regular monitoring of retinal non-perfusion and neovascularization may improve patient outcomes by allowing for timely interventions.

Conclusion

UWF FA represents a valuable tool in the management of diabetic retinopathy, providing critical insights into disease progression and treatment efficacy. Further studies are warranted to fully understand its impact on clinical outcomes.

References

1. Retinal Physician, Ultrawidefield Imaging for Diabetic Retinopathy, 2019 -- Extending the edge of discovery
2. Retinal Physician, Detection of Peripheral Retinal Nonperfusion in Diabetic Patients Using Ultrawidefield Imaging, 2023 -- A panoramic view could shape treatment of diabetic retinal disease
3. Retinal Physician, Replacing the Dilated Fundus Exam With Ultrawidefield Imaging in Asymptomatic Patients, 2023 -- Imaging without dilation may be the future in select patients
4. American Diabetes Association, Standards of Care in Diabetes—2026 -- Current guidance emphasizes systematic screening and timely treatment
5. PMC, Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy -- Landmark randomized data inform expectations after intravitreal therapy
6. Retinal Physician — Evolving Technology and New Terminology in Swept-Source OCT Angiography for Diabetic Retinopathy
7. The American Diabetes Association Releases “Standards of Care in Diabetes—2026” | American Diabetes Association
8. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy - PMC
9. Predicting intravitreal treatment response using ultrawide-field angiographic biomarkers in diabetic retinopathy - PMC